Posted inHematology-Oncology news
Venetoclax Dose Escalation Triggers a Rapid BAFF–BCL-2 Survival Axis in CLL: Implications for Resistance and Combination Strategies
Early venetoclax therapy rapidly induces a BAFF-driven upregulation of prosurvival BCL-2 family proteins in surviving CLL cells, suggesting homeostatic cytokine signaling limits depth and durability of response and identifying BAFF/MCL-1 pathways as candidate co-targets.